Literature DB >> 6208992

Progress toward therapeutic application of interferons, 1979-1983.

E C Borden.   

Abstract

Interferons differ chemically and biologically from other modalities of cancer treatment. They are proteins that inhibit viral replication, influence subcellular processes, slow cellular proliferation, affect cell differentiation, and modulate immune responses. These regulatory effects on cell function undoubtedly underlie the effects of interferons in malignant disease. As a result of efforts by academia, industry, governments, and organizations such as the American Cancer Society, significant progress has been made over the past 5 years in elucidating structure, improving production, and defining clinical applications of interferons for both virus and malignant disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208992     DOI: 10.1002/1097-0142(19841201)54:2+<2770::aid-cncr2820541425>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Accelerated genetic destabilization and dormancy: two distinct causes of resistance in metastatic cells; clinical magnitude, therapeutic approaches.

Authors:  L Israel
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

2.  Intralymphatic infusion of interferon in patients with lymph nodal metastases from melanoma of the lower limbs.

Authors:  E Sulis; C Floris; C Massidda
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines.

Authors:  J I Garrison; M E Berens; J R Shapiro; S Treasurywala; G Floyd-Smith
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

4.  Normal human epidermis contains an interferon-like protein.

Authors:  M Yaar; A V Palleroni; B A Gilchrest
Journal:  J Cell Biol       Date:  1986-10       Impact factor: 10.539

Review 5.  The role of interferons in the treatment of malignant neoplasms.

Authors:  J R Murren; A C Buzaid
Journal:  Yale J Biol Med       Date:  1989 May-Jun

Review 6.  The gamble between oncolytic virus therapy and IFN.

Authors:  Qingbo Li; Fengxian Tan; Yuanyuan Wang; Xiaohui Liu; Xianbin Kong; Jingyan Meng; Long Yang; Shan Cen
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

7.  Treatment of basal cell carcinoma with intralesional interferon alpha-2b.

Authors:  M F Healsmith; J Berth-Jones; A Fletcher; R A Graham-Brown
Journal:  J R Soc Med       Date:  1991-09       Impact factor: 18.000

8.  IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.

Authors:  Holger H H Erb; Regina V Langlechner; Patrizia L Moser; Florian Handle; Tineke Casneuf; Karin Verstraeten; Bettina Schlick; Georg Schäfer; Brett Hall; Kate Sasser; Zoran Culig; Frédéric R Santer
Journal:  Endocr Relat Cancer       Date:  2013-08-23       Impact factor: 5.678

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.